Skip to content

Lotus Biotech Development Corp.: 10-Q filed 2014-02-24

What Lotus Biotech Development Corp. reported in its quarterly report filed 2014-02-24 (fiscal Q3 2013): 10 published measures, 29 facts as tagged in accession 0001002014-14-000064.

This filing

Form
10-Q (quarterly report)
Filed
2014-02-24
Fiscal period
fiscal Q3 2013
Accession
0001002014-14-000064 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lotus Biotech Development Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-12-311,278USD
At 2013-03-314,069USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-12-31-21,042USD
At 2013-03-31-9,277USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-12-3169USD
At 2013-09-304,069USD
At 2013-03-314,069USD
At 2012-12-3115,569USD
At 2012-09-30411USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-11,765USD92
2013-04-01 to 2013-12-31-125,342USD275
2012-10-01 to 2012-12-31-37,992USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-10-01 to 2013-12-31309USD92
2013-04-01 to 2013-12-31-91,484USD275
2012-10-01 to 2012-12-31-48,708USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-3,100USD92
2013-04-01 to 2013-12-31113,196USD275
2012-10-01 to 2012-12-3163,866USD92

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-1,209USD92
2013-04-01 to 2013-12-31-21,643USD275

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-12-3122,320USD
At 2013-03-3113,346USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-12-31104,240USD
At 2013-03-31104,240USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-3,966USD92
2013-04-01 to 2013-12-31-11,765USD275
2011-03-24 to 2013-12-31-125,342USD1014
2012-10-01 to 2012-12-31-25,758USD92
2012-04-01 to 2012-12-31-37,992USD275

Inspect the source

Entity
Lotus Biotech Development Corp. / CIK 0001520592
Captured
SEC response SHA-256
bb66e059f830b74605654323cb1a568c3bcc71a4f51b0be18e8739c2eaf2c9b9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001520592.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))